Suchen Sie nach Informationen zu Orapharma-Hauptsitz? Folgen Sie den Links unten, um alle Informationen zu finden, die Sie benötigen, und mehr.
https://www.orapharma.com/
We provide dental professionals with tools and resources to educate patients on oral healthcare. Visit OraPharma professional education. We also collaborate with leading academic institutions and professional associations to benefit dental hygiene students and professionals. Notably, our Student Access program provides education and experience ...
https://www.dnb.com/business-directory/company-profiles.orapharma_inc.62d463cfed3e496a66948ce959913bf6.html
Company Description: Orapharma, Inc. is located in Bridgewater, NJ, United States and is part of the Home Health Care Services Industry. Orapharma, Inc. has 150 total employees across all of its locations and generates $26.40 million in sales (USD). (Sales figure is modelled). There are 205 companies in the Orapharma, Inc. corporate family.
https://www.orapharma.com/ossix/contact
Please direct any inquiries about the OSSIX portfolio to OraPharma:. Customer Service Phone Number: 1-866-273-7846
https://www.datanyze.com/companies/orapharma/59982455
OraPharma Profile and History . OraPharma, Inc. is a specialty pharmaceutical company that discovers, develops and commercializes therapeutics for the treatment of periodontal disease at various phases of progression. ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg ( www.arestin.com) is indicated as an adjunct to scaling and root ...
https://opencorporates.com/companies/us_ma/223473777
ORAPHARMA, INC. branch. Company Number 223473777 Previous Company Numbers. 001049610; Status Active Incorporation Date 29 March 2011 (over 11 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of ORAPHARMA, INC. (Delaware (US)) Registered Address. 400 SOMERSET CORPORATE BLVD.
https://www.frazierhealthcare.com/portfolio/orapharma
Orapharma is a specialty pharmaceuticals company focusing on developing and commercializing novel therapeutics to improve and maintain oral health. The company developed ARESTIN, an oral topical formulation of minocycline, that was approved by the FDA in 2001 for treatment of periodontal disease. Orapharma completed its IPO in 2000 and was acquired by J&J in 2002.
Wir hoffen, dass Sie über die obigen Links alle notwendigen Informationen zu Orapharma-Hauptsitz gefunden haben.
